Samchundang Pharm, the current market cap leader on KOSDAQ, made waves recently when Chief Executive Officer (CEO) Jeon In-seok announced plans to sell shares worth approximately 2.5 billion KRW (about 1.67 million USD). While share sales typically raise red flags, the company’s hint at forthcoming significant news has investors buzzing about potential future gains.
On Tuesday, the Financial Supervisory Service’s electronic disclosure system (DART) revealed that the CEO intends to offload 265,700 common shares through after-hours trading. The sale is scheduled between April 23 and May 22, spanning roughly 30 days, with an estimated value of 2.5 billion KRW (about 1.67 million USD).
The company was quick to emphasize that this sale is purely for tax-related purposes. In a letter to shareholders, the CEO stated that this sale is exclusively to cover tax obligations, including gift taxes, adding that it’s a personal matter unrelated to the company’s operational status or fundamentals.
Some market watchers have expressed concerns about a potential overhang effect, given that the share sale follows closely on the heels of the company’s rise to the top market cap position. They argue that the influx of 2.5 billion KRW (about 1.67 million USD) worth of shares could put pressure on supply over the coming weeks.
However, other analysts predict the impact will be minimal. A securities industry insider noted that usually, overhang issues trigger immediate stock price drops, which they’re not seeing here. Given the relatively small volume compared to the overall market cap and the after-hours trading method, market disruption should be limited.
Adding intrigue to the situation, the CEO hinted in his letter that negotiations with global pharmaceutical giants are nearing fruition, suggesting that a game-changing announcement may be imminent.
Samchundang Pharm is currently expanding its S-PASS platform pipeline, with a focus on oral insulin and obesity treatments, building on its successful commercialization of an Aflibercept biosimilar. Industry experts predict biosimilars will drive short-term growth, while the oral platform-based drugs are expected to fuel long-term expansion.
The company’s stock recently surged following news that it had completed applications for Phase 1 and 2 clinical trials of its oral insulin in Europe, propelling it to the top spot in KOSDAQ market capitalization on March 20.
